Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors.

One facet of cytokine receptor signaling involves the activation of signal transducers and activators of transcription (STATs). STATs are rapidly activated via tyrosine phosphorylation by Janus kinase (JAK) family members and subsequently inactivated within a short period. We investigated the effect of proteasome inhibition on interleukin-3 (IL-3) activation of the JAK/STAT pathway following stimulation of Ba/F3 cells. Treatment of Ba/F3 cells with the proteasome inhibitor, N-acetyl-L-leucinyl-L-leucinyl-norleucinal (LLnL), led to stable tyrosine phosphorylation of the IL-3 receptor, beta common (betac), and STAT5 following stimulation. The effects of LLnL were not restricted to the JAK/STAT pathway, as Shc and mitogen-activated protein kinase (MAPK) phosphorylation were also prolonged in LLnL-treated cells. Further investigation showed these stable phosphorylation events were the result of prolonged activation of JAK2 and JAK1. These observations were confirmed using pharmacologic inhibitors. In the presence of LLnL, stable phosphorylation of STAT5 and betac was abrogated if the tyrosine kinase inhibitor, staurosporine, was added. The effect of staurosporine on STAT5 phosphorylation could be overcome if the phosphatase inhibitor, vanadate, was also added, suggesting phosphorylated STAT5 could be stabilized by phosphatase, but not by proteasome inhibition per se. These observations are consistent with the hypothesis that proteasome-mediated protein degradation can modulate the activity of the JAK/STAT pathway by regulating the deactivation of JAK.

[1]  G. Feng,et al.  Molecular Characterization of Specific Interactions between SHP-2 Phosphatase and JAK Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.

[2]  M. Hochstrasser.  Ubiquitin-dependent protein degradation. , 1996, Annual review of genetics.

[3]  S. Gerstberger,et al.  Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation , 1995, Science.

[4]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[5]  B. Groner,et al.  Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. , 1994, The EMBO journal.

[6]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[7]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Groner,et al.  Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype , 1996, Molecular and cellular biology.

[9]  I. Verma,et al.  Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Darnell,et al.  The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. , 1996, The EMBO journal.

[11]  K. Xia,et al.  Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. , 1997, Blood.

[12]  A. Miyajima,et al.  Suppression of interleukin‐3‐induced gene expression by a C‐terminal truncated Stat5: role of Stat5 in proliferation. , 1996, The EMBO journal.

[13]  J. Ihle,et al.  Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis , 1993, Molecular and cellular biology.

[14]  L. Platanias,et al.  Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 , 1996, Molecular and cellular biology.

[15]  T. Maniatis,et al.  Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. , 1995, Genes & development.

[16]  M. Kirschner,et al.  A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B , 1995, Cell.

[17]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[18]  H. Pahl,et al.  Phosphorylation of human I kappa B‐alpha on serines 32 and 36 controls I kappa B‐alpha proteolysis and NF‐kappa B activation in response to diverse stimuli. , 1995, The EMBO journal.

[19]  M. Carroll,et al.  DUB-1, a deubiquitinating enzyme with growth-suppressing activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Ichihara,et al.  Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response. , 1996, Blood.

[21]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[22]  A. Miyajima,et al.  Interleukin‐3, granulocyte‐macrophage colony stimulating factor and interleukin‐5 transduce signals through two STAT5 homologs. , 1995, The EMBO journal.

[23]  I. Clark-lewis,et al.  Tyrosine phosphorylation of receptor beta subunits and common substrates in response to interleukin-3 and granulocyte-macrophage colony-stimulating factor. , 1992, The Journal of biological chemistry.

[24]  E. Liu,et al.  Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  J. Ihle,et al.  Naturally occurring dominant negative variants of Stat5 , 1996, Molecular and cellular biology.

[26]  N. Miyasaka,et al.  Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. , 1996, Blood.

[27]  D. Cantrell,et al.  Interleukin‐2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. , 1996, The EMBO journal.

[28]  B. Futcher,et al.  p34Cdc28-mediated control of Cln3 cyclin degradation , 1995, Molecular and cellular biology.

[29]  A. Gotoh,et al.  Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. , 1994, Blood.

[30]  M. Kirschner,et al.  Ubiquitination of the G1 cyclin Cln2p by a Cdc34p‐dependent pathway. , 1995, The EMBO journal.

[31]  H. Erdjument-Bromage,et al.  Interleukin‐3 signals through multiple isoforms of Stat5. , 1995, The EMBO journal.

[32]  J. Tavernier,et al.  Characterization of the murine IL-5 receptor complex with the use of a panel of monoclonal antibodies. Relationship to the murine IL-3 receptor. , 1991, Journal of immunology.

[33]  K. Takatsu,et al.  Critical proline residues of the cytoplasmic domain of the IL-5 receptor alpha chain and its function in IL-5-mediated activation of JAK kinase and STAT5. , 1996, International immunology.

[34]  Kim Nasmyth,et al.  Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle , 1994, Cell.

[35]  Howard Riezman,et al.  Ubiquitination of a Yeast Plasma Membrane Receptor Signals Its Ligand-Stimulated Endocytosis , 1996, Cell.

[36]  L. Staszewski,et al.  Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. , 1994, Cell.

[37]  A. Schwartz,et al.  Linkage of the ubiquitin‐conjugating system and the endocytic pathway in ligand‐induced internalization of the growth hormone receptor , 1997, The EMBO journal.

[38]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[39]  J. Tavernier,et al.  Characterization of critical residues in the cytoplasmic domain of the human interleukin‐5 receptor α chain required for growth signal transduction , 1995, European journal of immunology.

[40]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.

[41]  K. Norga,et al.  Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. , 1997, Blood.

[42]  J. Briscoe,et al.  JAKs and STATs branch out. , 1996, Trends in cell biology.

[43]  S. Nagata,et al.  Unidirectional cross-phosphorylation between the granulocyte colony-stimulating factor and interleukin 3 receptors. , 1993, The Journal of biological chemistry.

[44]  S. Burakoff,et al.  Involvement of Proteasomes in Regulating Jak-STAT Pathways upon Interleukin-2 Stimulation* , 1997, The Journal of Biological Chemistry.

[45]  A. Goldberg,et al.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.

[46]  L. Ivashkiv,et al.  Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Bruce Futcher,et al.  Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins , 1995, Nature.

[48]  V. Duronio,et al.  Genetic basis of hypo-responsiveness of A/J mice to interleukin-3. , 1996, Blood.

[49]  T. Maniatis,et al.  Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. , 1996, Science.

[50]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[51]  J. Cleveland,et al.  Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. He,et al.  Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway , 1995, The Journal of Biological Chemistry.

[53]  M. Steinmetz,et al.  IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivo , 1985, Cell.

[54]  S Goelz,et al.  Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 , 1995, Molecular and cellular biology.

[55]  T. Roberts,et al.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways , 1997, Molecular and cellular biology.

[56]  J. Ihle.  STATs: Signal Transducers and Activators of Transcription , 1996, Cell.

[57]  A. Schwartz,et al.  Growth Hormone-induced Signal Transduction Depends on an Intact Ubiquitin System* , 1997, The Journal of Biological Chemistry.